Quantcast

Latest Ganirelix Stories

2011-05-11 12:50:38

Gonadotrophin-releasing hormone antagonists as effective as agonists with fewer serious harmful effects With new information available, authors of a Cochrane Systematic Review have revised their conclusions about the relative effectiveness of two different treatments used to help women become pregnant. They now conclude that giving women gonadotrophin-releasing hormone (GnRH) antagonists leads to similar live-birth rates compared with GnRH agonists. Previously they had concluded that women...

2011-05-11 07:36:23

(Ivanhoe Newswire) -- Giving women gonadotrophin-releasing hormone (GnRH) antagonists leads to similar live-birth rates compared with GnRH agonists, according to a new study. Previous research had concluded that women who used antagonists tended to have lower birth-rates than those using agonists. This is important because the research also showed that GnRH antagonists can halve the risk of over-stimulating the ovaries compared with GnRH agonists, as well as halving the number of women who...

2009-12-23 14:12:21

Previous work in birds and sheep shows a wealth of clinical possibilities Nearly 10 years after the discovery that birds make a hormone that suppresses reproduction, University of California, Berkeley, neuroscientists have established that humans make it too, opening the door to development of a new class of contraceptive and possible treatments for cancer or other diseases. The hormone, gonadotropin inhibitory hormone (GnIH), has the opposite effect from gonadotropin releasing hormone, a key...

2009-10-20 08:00:00

ATLANTA, Oct. 20 /PRNewswire/ -- Ferring Pharmaceuticals presented an interim study analysis indicating that MENOPUR® (menotropins for injection, USP) is effective in in vitro fertilization (IVF) cycles using a gonadotropin-releasing hormone (GnRH) antagonist. The results were presented in a poster at the 65th Annual Meeting of the American Society for Reproductive Medicine (ASRM) in Atlanta, October 17-21, 2009. MENOPUR® vs. rFSH in GnRH Antagonist...

2009-08-04 07:55:00

PARSIPPANY, N.J., Aug. 4 /PRNewswire/ -- Ferring Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved the trade name FIRMAGON(R) (degarelix for injection) for its prostate cancer treatment previously marketed under the generic name degarelix. FIRMAGON is a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for patients with advanced prostate cancer. Since initial market introduction under the generic name degarelix,...

2008-09-04 12:00:07

Neurocrine Biosciences, a biopharmaceutical company, has announced positive safety and efficacy results from its third Phase II clinical trial using its proprietary, orally-active nonpeptide gonadotropin-releasing hormone receptor antagonist, elagolix, in patients with endometriosis. The Petal study enrolled 252 patients, with a confirmed diagnosis of endometriosis, into three treatment groups - elagolix 150mg once daily, elagolix 75mg twice daily, or depo-subQ provera 104 (DMPA) for six...


Word of the Day
bibliopole
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'
Related